Your browser doesn't support javascript.
loading
Clinical Investigation of Large Volume Subcutaneous Delivery up to 25 mL for Lean and Non-Lean Subjects.
Dang, Xiangnan; Shih, Han; Sharma, Rakesh; Angwin-Kaerner, Daneen T; Lin, Kathleen; Kapur, Shiven; Thyagarajapuram, Nagarajan R; Shi, Galen H; Collins, David S.
Afiliação
  • Dang X; Eli Lilly and Company, Cambridge, Massachusetts, 02142, United States of America.
  • Shih H; Eli Lilly and Company, Lilly Technology Center, Indianapolis, Indiana, 46221, United States of America. hannie.shih@lilly.com.
  • Sharma R; Eli Lilly and Company, Lilly Capability Center India, Bangalore, 560103, Karnataka, India.
  • Angwin-Kaerner DT; Eli Lilly and Company, Louisville, Colorado, 80027, United States of America.
  • Lin K; Eli Lilly and Company, Cambridge, Massachusetts, 02142, United States of America.
  • Kapur S; Eli Lilly and Company, Lilly Technology Center, Indianapolis, Indiana, 46221, United States of America.
  • Thyagarajapuram NR; Eli Lilly and Company, Lilly Capability Center India, Bangalore, 560103, Karnataka, India.
  • Shi GH; Eli Lilly and Company, Lilly Technology Center, Indianapolis, Indiana, 46221, United States of America.
  • Collins DS; Eli Lilly and Company, Lilly Technology Center, Indianapolis, Indiana, 46221, United States of America.
Pharm Res ; 41(4): 751-763, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38443633
ABSTRACT

PURPOSE:

To evaluate the clinical feasibility and tolerability of large volume subcutaneous delivery at different injection depths for lean and non-lean subjects.

METHODS:

A single-center, randomized, subject-blinded, crossover study in 62 healthy subjects was conducted to evaluate delivery of a 10-cP solution containing hyaluronic acid. Subjects were separated into lean and non-lean cohort by SC thickness. A syringe pump was used to study the effect of different volumes (5, 12, 25 mL) of a viscous placebo solution and needle lengths (6, 9 and 12 mm) delivered at 0.5 mL/min.

RESULTS:

Across all treatments, injection sites were observed to have negligible leakage, ~34 kPa of back pressure, and VAS of mild pain with higher pain from needle insertion than during injection. While mild to moderate erythema was the most frequently reported ISR and edema was most prominent for 25 mL injections, all ISRs were resolved within 4 hours post injection. Subjects were unbothered by ISRs across all treatments and rated them as low distress scores (average 1.0-1.5 out of 6).

CONCLUSION:

SC injection of 25 mL is feasible and tolerable using a low-pain formulation for abdomen injection irrespective of subcutaneous thickness and injection depths at a delivery rate of 0.5 mL/min.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dor / Tela Subcutânea Limite: Humans Idioma: En Revista: Pharm Res Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dor / Tela Subcutânea Limite: Humans Idioma: En Revista: Pharm Res Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos